Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout

19 novembre 2026 aggiornato da: ScandiBio Therapeutics AB

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Efficacy, Safety, and Tolerability of Combined Metabolic Activator (CMA2) Supplementation in Individuals With Hyperuricemia Associated With Gout

This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine for 4 weeks.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Consenting participants will be screened for eligibility (Visit 1; screening) according to study-specific eligibility criteria within 7 days prior to randomisation and start of investigational medicinal product (IMP) administration.

Eligible participants will be randomised on Day 1 (Visit 2) to 4 weeks of twice daily (b.i.d.) oral treatment of either CMA2 or placebo (1:1). The first dose will be administered at the study clinic. The participants will be observed for 2 hours post dose for the development of any allergic reactions or intolerance after taking the first dose.

Visits at the study site will be performed at Day 1 (Visit 2), Day 14 (Visit 4) and Day 28 (Visit 6; end of in study treatment). There will be telephone follow up visits at Day 7 (Visit 3) and Day 21(Visit 5) checking safety, concomitant medications and IMP compliance. A final follow-up visit for safety assessments will be conducted in a subgroup of patients 14 days after the end of treatment (Day 42; Visit 7) during an IMP-free follow-up period to assess safety and concomitant medications.

The following clinical scales will be used to evaluate the effect of CMA2 on uric acid decline, hsCRP and daily life activity: Serum Uric Acid Levels, hsCRP, number of flares according to the GAFFO criteria, HAQ-DI, SF-36, PGA (100 mm).

Plasma samples will be collected for advanced metabolomics, proteomics, and lipidomics analysis.

Optionally, synovial samples will be collected for advanced metabolomics, proteomics, and lipidomics analysis. Optionally, gut and saliva samples will be collected for metagenomics analysis of gut and oral microbiome.

Laboratory and clinical safety parameters will be monitored at pre-specified time-points.

Tipo di studio

Interventistico

Iscrizione (Stimato)

336

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Gökhan Gönenli, Uzm. Dr. M.
  • Numero di telefono: + 90 532 405 76 82
  • Email: mgonenli@ku.edu.tr

Backup dei contatti dello studio

  • Nome: Müjdat Zeybel, Prof. Dr.
  • Numero di telefono: + 90 532 604 83 81
  • Email: mzeybel@ku.edu.tr

Luoghi di studio

      • Ankara, Turchia (Türkiye)
        • Non ancora reclutamento
        • Ankara Bilkent City Hospital
        • Contatto:
          • Hakan Babaoğlu
        • Investigatore principale:
          • Hakan Babaoğlu, Assoc. Prof. Dr.
      • Antalya, Turchia (Türkiye)
        • Non ancora reclutamento
        • Alanya Training and Research Hospital
        • Contatto:
          • Şakir Özgür Keskek
        • Investigatore principale:
          • Şakir Özgür Keskek, Prof. Dr.
      • Erzurum, Turchia (Türkiye)
        • Non ancora reclutamento
        • Atatürk University Research Hospital
        • Contatto:
          • Bülent Albayrak
        • Investigatore principale:
          • Bülent Albayrak, Assoc. Prof. Dr.
      • Erzurum, Turchia (Türkiye)
        • Non ancora reclutamento
        • Erzurum City Hospital
        • Contatto:
          • Kenan Çadırcı
        • Investigatore principale:
          • Kenan Çadırcı, Prof. Dr.
      • Eskişehir, Turchia (Türkiye)
        • Reclutamento
        • Eskişehir Osmangazi University Faculty of Medicine Hospital
        • Contatto:
          • Nazife Şule Bige Yaşar
        • Investigatore principale:
          • Nazife Şule Bige Yaşar, Prof. Dr.
      • Istanbul, Turchia (Türkiye)
        • Non ancora reclutamento
        • Göztepe Prof. Dr. Süleyman Yalçın City Hospital
        • Contatto:
          • Esen Kasapoğlu
        • Investigatore principale:
          • Esen Kasapoğlu, Prof. Dr.
      • Istanbul, Turchia (Türkiye)
        • Non ancora reclutamento
        • Istanbul University-Cerrahpaşa Faculty of Medicine Hospital
        • Contatto:
          • Gülen Hatemi
        • Investigatore principale:
          • Gülen Hatemi, Prof. Dr.
      • Istanbul, Turchia (Türkiye)
        • Non ancora reclutamento
        • Kanuni Sultan Süleyman Training and Research Hospital
        • Contatto:
          • Ozan Cemal İçaçan
        • Investigatore principale:
          • Ozan Cemal İçaçan, Specialist. Dr.
      • Istanbul, Turchia (Türkiye)
        • Non ancora reclutamento
        • Kartal Dr. Lütfi Kırdar City Hospital
        • Contatto:
          • Mehmet Engin Tezcan
        • Investigatore principale:
          • Mehmet Engin Tezcan, Specialist. Dr.
      • Istanbul, Turchia (Türkiye)
        • Reclutamento
        • Koç University Hospital
        • Contatto:
        • Investigatore principale:
          • Gökhan Gönenli, Specialist. Dr.
      • Istanbul, Turchia (Türkiye)
        • Non ancora reclutamento
        • Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital
        • Contatto:
          • Kadem Arslan
        • Investigatore principale:
          • Kadem Arslan, Assoc. Prof. Dr.
      • Istanbul, Turchia (Türkiye)
        • Non ancora reclutamento
        • Sultan 2nd Abdülhamid Han Training and Research Hospital
        • Contatto:
          • Memnune Sena Ulu
        • Investigatore principale:
          • Memnune Sena Ulu, Prof. Dr.

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Men and women ≥ 18 years of age.
  2. Individuals with elevated uric acid blood levels (7 mg/dl) and at least one episode of gout during the last three years.
  3. Diagnosis of gout based on 2015 American College of Rheumatology-European Union League Against Rheumatism (ACR-EULAR) criteria.
  4. Able to give written informed consent for participation in the study by the patient and/or legal representatives.

Exclusion Criteria:

  1. Patients who have received uric acid-lowering therapy with a change in dose within 1 month prior to inclusion.

  2. Acute gout flare within 14 days prior to randomization (i.e., any gouty arthritis episode with pain or swelling that has not fully resolved ≤14 days before randomization). Definition of Resolved (for the eligibility assessment): absence of joint pain at rest and no visible swelling at the previously affected joint(s) for at least 48 hours, and no requirement for escalation of anti-inflammatory therapy within that period.

  3. History of stroke.

  4. History of brain trauma < 14 days.

  5. Uncontrolled diagnosed depression.

  6. Uncontrolled diabetes (HbA1c > 8.4%).

  7. Severe swallowing problems.

  8. PEG-feeding.

  9. Chronic diarrhoea.

  10. Chronic kidney disease with S-creatinine > 1.30 mg/dL.

  11. Estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73 m2 in the Screening Phase

  12. Active bronchial asthma at the time of screening.

  13. History of phenylketonuria

  14. Known allergy for substances used in the study

  15. Known allergy for strawberry

  16. Known active malignancy

  17. Known active psoriasis

  18. Use of dietary supplements such as vitamins, omega-3 products, or plant stanol/sterol products later than one (1) week prior to inclusion.

  19. Use of anti-microbial agents later than one (1) week prior to inclusion.

  20. Drug and/or alcohol abuse.

  21. Participants considered as inappropriate for this study for any reason (noncompliance etc.) per investigator assessment.

  22. Administration of another new chemical entity (defined as a compound that has not been approved for marketing) or has participated in any other clinical study that included drug treatment with the last administration within 3 months prior to administration of IMP in this study.

  23. Females who are breastfeeding or pregnant at screening (as documented by a positive beta human chorionic gonadotropin [β-hCG] test)

  24. Females of childbearing potential who:

    Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:

    • total abstinence (if it is their preferred and usual lifestyle)
    • an intrauterine device or intrauterine hormone-releasing system (IUS)
    • a contraceptive implant
    • an oral contraceptive (Subject must have been on a stable dose of the same oral contraceptive product for at least 28 days before dosing and must agree to stay on the same dose of the oral contraceptive throughout the study and for 28 days after study drug discontinuation.)
    • have a vasectomized partner with confirmed azoospermia. Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation.

    It is permissible that if a highly effective method of contraception is not appropriate or acceptable to the subject, then the subject must agree to use a medically acceptable method of contraception, ie, double-barrier methods of contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap with spermicide.

    NOTE: Females of childbearing potential must have documented tubal ligation or hysterectomy; or be post-menopausal (defined as 12 months of amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 25-140 IE/L and estradiol <200 pmol/L is confirmatory]).

  25. Male participants who:

    1. Plan to conceive a child or donate sperm during the study treatment period and for at least 90 days after the last dose of investigational product, or
    2. Are unwilling to use effective contraception during the study and for at least 90 days after the last dose of investigational product.
  26. Currently has secondary hyperuricemia:

1) Lesch-Nyhan syndrome 2) Phosphoribosylpyrophosphate synthetase superactivity 3) Congenital myogenic hyperuricemia 4) Hematopoietic neoplasms (acute leukemia, lymphoma malignant, myeloproliferative disorder, myelodysplastic syndrome, etc) 5) Solid tumors (breast cancer, seminoma, sarcoma, Wilms tumor, small cell lung cancer, etc) 6) Non-neoplastic diseases (psoriasis vulgaris, secondary polycythemia, hemolytic anemia) 7) Rhabdomyolysis 8) Hypothyroidism 9) Polycystic kidney 10) Lead poisoning/lead nephropathy 11) Down's syndrome 12) Familial juvenile gouty nephropathy 13) Hyperlactacidemia 14) Glycogen storage disease type 1 27. Participants who are on the following treatment are required to be on a stable dose and same mode of administration for at least 14 days prior to screening and to keep the stable during the study. Participants are not permitted to initiate these drugs within 14 days prior to screening and during the study.

  • Dietary and physical therapy for the underlying disease
  • Drugs or containing compound preparations that potentially affect SUA level:
  • Immunosuppressants (mizoribine, cyclosporin, tacrolimus hydrate)
  • Antituberculous drugs (pyrazinamide, ethambutol hydrochloride)
  • Hyperlipidemia drugs (fenofibrate, atorvastatin, rosuvastatin, pitavastatin)
  • Antihypertensives (losartan potassium)
  • Diuretics (thiazide diuretics, loop diuretics)
  • Sodium-dependent glucose transporter (SGLT) 2 inhibitors
  • Theophylline

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Braccio di trattamento

A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withdrawn from the study.

Comparatore placebo: Braccio placebo

As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To evaluate the effect of 4-weeks administration of CMA2 treatment on serum uric acid levels in participants diagnosed with hyperuricemia associated with gout, as compared with placebo.
Lasso di tempo: 4 weeks

Absolute change in serum uric acid levels from baseline to end-of-treatment (4 weeks).

4 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To evaluate the effect of 4 weeks of CMA2 treatment on patient global assessment (PGA, 100 mm) compared with placebo.
Lasso di tempo: 4 weeks

Change in Patient Global Assessment (PGA, 100 mm) score from baseline to end-of-treatment. PGA is assessed using a visual analogue scale (VAS) ranging from 0 to 10 or 0 to 100, where higher scores indicate worse disease activity.

4 weeks
To evaluate the effect of 4 weeks of CMA2 treatment on High Sensitivity C-reactive Protein (hsCRP) levels compared with placebo.
Lasso di tempo: 4 weeks

Percentage change in High Sensitivity C-reactive Protein (hsCRP) levels from baseline to end-of-treatment.

4 weeks
To evaluate the proportion of participants achieving serum uric acid levels < 6 mg/dL.
Lasso di tempo: 4 weeks

Proportion of patients with a serum uric acid level <6 .0 mg/dL at end-of-treatment.

4 weeks
To evaluate the effect of 2-weeks administration of CMA2 treatment on serum uric acid levels compared with placebo.
Lasso di tempo: 2 weeks

Change in serum uric acid levels from baseline to 2-weeks.

2 weeks
To evaluate patient adherence to the twice-daily treatment regimen.
Lasso di tempo: 4 weeks

Percentage of expected twice-daily study drug doses successfully administered, as assessed by sachet counts.

4 weeks
To evaluate the incidence of adverse events (AEs).
Lasso di tempo: 6 weeks

The percentage of subjects experiencing at least one AE during the study period.

6 weeks
To evaluate the severity of AEs.
Lasso di tempo: 6 weeks

The incidence of AEs categorized by maximum severity grade.

6 weeks
To evaluate the incidence of serious adverse events (SAEs).
Lasso di tempo: 6 weeks

The percentage of subjects experiencing at least one SAE during the study period.

6 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Gökhan Gönenli, Uzm. Dr. M., Koc University Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 novembre 2026

Completamento primario (Stimato)

1 febbraio 2027

Completamento dello studio (Stimato)

1 febbraio 2027

Date di iscrizione allo studio

Primo inviato

15 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 ottobre 2026

Primo Inserito (Effettivo)

22 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

19 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • SB-GOUT-001

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .